C

Checkpoint Therapeutics
D

CKPT

3.46000
USD
0.10
(2.98%)
مغلق
حجم التداول
13,784
الربح لكل سهم
0
العائد الربحي
0
P/E
-2
حجم السوق
155,761,730
نظرة عامةالتوصياتالأفكار والتحليلاتالأخبار
أصول ذات صلة
    B
    BLRX
    -0.09800
    (-12.41%)
    0.69200 USD
    C
    CLDX
    -0.540
    (-1.42%)
    37.560 USD
    E
    EVOK
    4.38330
    (1,077.77%)
    4.79000 USD
    K
    KRTX
    0
    (0%)
    0.000000 USD
    O
    OCUL
    -0.40000
    (-4.72%)
    8.07000 USD
    P
    PIRS
    0.480
    (2.91%)
    16.990 USD
    R
    RVMD
    -0.460
    (-1.01%)
    45.270 USD
    S
    SLS
    0.08000
    (6.90%)
    1.24000 USD
    S
    SNDX
    -0.750
    (-3.30%)
    21.990 USD
    المزيد
الأخبار
المقالات

العنوان: Checkpoint Therapeutics

القطاع: Healthcare
الصناعة: Biotechnology
Checkpoint Therapeutics Inc is an immuno-oncology biopharmaceutical company based in the USA. It focuses on the acquisition, development, and commercialization of novel, non-chemotherapy, immune-enhanced combination treatments for patientswith solid tumor cancers. Its licensed portfolio of antibodies includes targeting programmed cell death-ligand 1 (PD-L1), glucocorticoid-induced TNFR-related protein (GITR) and carbonic anhydrase IX (CAIX). The company is evaluating its lead small-molecule, targeted anti-cancer agent, olafertinib, a third-generation epidermal growth factor receptor ("EGFR") inhibitor, as a potential new treatment for patients with EGFR mutation-positive non-small cell lung cancer.